Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598585 | 1.00 | GPR183 (1.00) | GPR183KCNH2 | |
| SCHEMBL26093881 | 0.96 | GPR183 (0.93) | GPR183KCNH2 | |
| SCHEMBL30374883 | 0.87 | GPR183 (0.77) | GPR183KCNH2 | |
| SCHEMBL16598422 | 0.86 | GPR183 (1.00) | GPR183KCNH2 | |
| SCHEMBL16598425 | 0.86 | GPR183 (1.00) | GPR183KCNH2 | |
| SCHEMBL26487595 | 0.85 | GPR183 (0.73) | GPR183KCNH2 | |
| SCHEMBL26093146 | 0.85 | GPR183 (0.75) | GPR183KCNH2 | |
| SCHEMBL26089470 | 0.85 | GPR183 (0.73) | GPR183KCNH2 | |
| SCHEMBL26094471 | 0.85 | GPR183 (0.79) | GPR183KCNH2 | |
| SCHEMBL16598548 | 0.84 | GPR183 (1.00) | GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419511-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd (CN) | 2024-08-28 | — | — | EP | claimed |
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| EP-4676918-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | Nanjing Immunophage Biomedical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250034121-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| EP-4497440-A1 | USE OF 7-TRIFLUOROMETHYL-7ALPHA,25-DIHYDROXYCHOLESTEROL IN THE TREATMENT AND MODULATION OF AUTOIMMUNE AND INFLAMMATORY DISEASES OF THE NERVOUS SYSTEM AND NEURODEGENERATIVE DISEASES | Gdanski Uniwersytet Medyczny (PL) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024208303-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2024-10-10 | — | — | WO | disclosed |
| WO-2024179405-A1 | CLASS OF CINNAMAMIDE DERIVATIVES AND APPLICATION THEREOF | 上海交通大学 | 2024-09-06 | — | — | WO | disclosed |
| EP-4419511-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-118546081-A | Cinnamide derivative and application thereof | 上海交通大学 | 2024-08-27 | — | — | CN | disclosed |
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| WO-2015048570-A2 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | GPR183 22/4885KCNH2 3147/4885 |
| US-20250034121-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | GPR183, GPR180, GPR65 | GPR183 1/4885KCNH2 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.